NeuralStem Inc. Announces 2013 Financial Results

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013.

"2013 was an exciting year for advancement in our NSI-566 cell therapy clinical programs," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer.

Help employers find you! Check out all the jobs and post your resume.